IL126972A0 - Stimulation of host defense mechanisms against viral challenges - Google Patents

Stimulation of host defense mechanisms against viral challenges

Info

Publication number
IL126972A0
IL126972A0 IL12697297A IL12697297A IL126972A0 IL 126972 A0 IL126972 A0 IL 126972A0 IL 12697297 A IL12697297 A IL 12697297A IL 12697297 A IL12697297 A IL 12697297A IL 126972 A0 IL126972 A0 IL 126972A0
Authority
IL
Israel
Prior art keywords
stimulation
host defense
defense mechanisms
against viral
mechanisms against
Prior art date
Application number
IL12697297A
Other languages
English (en)
Original Assignee
Pharma Pacific Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Pacific Pty Ltd filed Critical Pharma Pacific Pty Ltd
Publication of IL126972A0 publication Critical patent/IL126972A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
IL12697297A 1996-05-09 1997-05-05 Stimulation of host defense mechanisms against viral challenges IL126972A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPN9765A AUPN976596A0 (en) 1996-05-09 1996-05-09 Stimulation of host defence mechanisms
PCT/IB1997/000489 WO1997041883A1 (fr) 1996-05-09 1997-05-05 Stimulation des mecanismes de defense hotes contre des attaques virales

Publications (1)

Publication Number Publication Date
IL126972A0 true IL126972A0 (en) 1999-09-22

Family

ID=3794078

Family Applications (2)

Application Number Title Priority Date Filing Date
IL12697297A IL126972A0 (en) 1996-05-09 1997-05-05 Stimulation of host defense mechanisms against viral challenges
IL12697097A IL126970A0 (en) 1996-05-09 1997-05-05 Stimulation of host defense mechanisms against tumors

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL12697097A IL126970A0 (en) 1996-05-09 1997-05-05 Stimulation of host defense mechanisms against tumors

Country Status (17)

Country Link
EP (2) EP0898478B1 (fr)
JP (2) JP3806444B2 (fr)
KR (2) KR100399499B1 (fr)
CN (1) CN1154508C (fr)
AR (2) AR007058A1 (fr)
AT (2) ATE316791T1 (fr)
AU (3) AUPN976596A0 (fr)
BR (2) BR9709066A (fr)
CA (2) CA2253908A1 (fr)
DE (2) DE69735201T2 (fr)
ES (2) ES2260794T3 (fr)
ID (2) ID16885A (fr)
IL (2) IL126972A0 (fr)
NZ (2) NZ332688A (fr)
TW (1) TW528599B (fr)
WO (2) WO1997041883A1 (fr)
ZA (1) ZA973988B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6299871B1 (en) * 1998-07-24 2001-10-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Orally-administrable therapeutic and/or prophylactic agent for HTLV-1-related diseases
CA2374301A1 (fr) * 1999-05-26 2000-11-30 Brigham And Women's Hospital, Inc. Utilisations therapeutiques d'agents modulant l'activite de l'actine alpha de muscle lisse
US6710025B1 (en) 1999-05-26 2004-03-23 The Brigham And Women's Hospital, Inc. Treatment of damaged tissue using agents that modulate the activity of alpha-smooth muscle actin
US20040258663A1 (en) * 2003-05-08 2004-12-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon alpha
ES2294589T3 (es) 2004-04-29 2008-04-01 F. Hoffmann-La Roche Ag Variacion de la secuencia nucleosida de ns5a como marcador.
DE102007014752A1 (de) 2007-03-28 2008-10-02 Dusek, Niels, Dr. Verwendung von humanidentischem oder humanaequivalentem rekombinantem Interleukin-2 (heqlL-2) als Therapeutikum in der Human- und Veterinärmedizin

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982000588A1 (fr) * 1980-08-22 1982-03-04 Illinois Univ Administration de composants biologiquement actifs d'isolats d'interferons d'especes heterologues
US5286748A (en) * 1981-01-05 1994-02-15 Eby Iii George A General method of shortening the duration of common colds by application of medicaments to tissues of oral cavity
US4820515A (en) * 1982-12-13 1989-04-11 Texas A&M University System Method of using interferon in low dosage to regulate appetite and efficiency of food utilization
US4605555A (en) * 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
IL76591A0 (en) * 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
JP2704546B2 (ja) * 1989-04-04 1998-01-26 光利 太良 Ａｔｌｌ治療用吸入剤
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5215741A (en) * 1990-10-30 1993-06-01 Amarillo Cell Culture Company, Incorporated Method for prevention of parasite infections
ZA919769B (en) * 1990-12-14 1992-09-30 Schering Corp Oral administration of alpha intereron to treat lung malignancies
US5780021A (en) * 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
IL113280A (en) * 1994-04-12 2004-12-15 Res Dev Foundation A preparation for the treatment of self-immunization diseases with the help of interferon of one type
AU724689B2 (en) * 1996-05-09 2000-09-28 Pharma Pacific Pty Ltd Method of treatment

Also Published As

Publication number Publication date
EP0898478B1 (fr) 2006-02-01
AR007058A1 (es) 1999-10-13
ES2260794T3 (es) 2006-11-01
JP3806446B2 (ja) 2006-08-09
DE69735201T2 (de) 2006-09-21
BR9709066A (pt) 2000-01-04
WO1997041886A1 (fr) 1997-11-13
DE69735201D1 (de) 2006-04-13
NZ332688A (en) 2000-07-28
KR100399501B1 (ko) 2003-12-18
AUPN976596A0 (en) 1996-05-30
CN1218409A (zh) 1999-06-02
EP0898478A4 (fr) 1999-05-26
ZA973988B (en) 1998-11-09
AU2710997A (en) 1997-11-26
EP0956040A1 (fr) 1999-11-17
KR20000010882A (ko) 2000-02-25
BR9709223A (pt) 2000-12-12
AU2399297A (en) 1997-11-26
EP0898478A1 (fr) 1999-03-03
WO1997041883A1 (fr) 1997-11-13
CA2253902A1 (fr) 1997-11-13
TW528599B (en) 2003-04-21
JP2000504027A (ja) 2000-04-04
CA2253908A1 (fr) 1997-11-13
JP3806444B2 (ja) 2006-08-09
ATE316793T1 (de) 2006-02-15
AR007059A1 (es) 1999-10-13
EP0956040B1 (fr) 2006-02-01
ATE316791T1 (de) 2006-02-15
AU724190B2 (en) 2000-09-14
EP0956040A4 (fr) 1999-11-17
ID16885A (id) 1997-11-20
ID16886A (id) 1997-11-20
JP2000504026A (ja) 2000-04-04
IL126970A0 (en) 1999-09-22
DE69735204T2 (de) 2006-09-21
KR100399499B1 (ko) 2003-12-18
ES2260790T3 (es) 2006-11-01
CN1154508C (zh) 2004-06-23
AU729514B2 (en) 2001-02-01
KR20000010880A (ko) 2000-02-25
NZ332690A (en) 2000-07-28
DE69735204D1 (de) 2006-04-13

Similar Documents

Publication Publication Date Title
ZA979096B (en) Viral and cancer treatment
IL135673A0 (en) Therapeutic uses of quinoline derivatives
NO984163L (no) Forbedret syn ved fotodynamisk terapi av °yet
GB9622500D0 (en) Therapeutic gene
EP0851765A4 (fr) Procedes therapeutique et profilactique utilisant des proteines du choque thermique
IL134718A0 (en) Treatment of conduct disorder
ID18679A (id) Penggunaan terapi lanjutan
ZA973987B (en) Stimulation of host defence mechanisms against viral challenges
GB9700939D0 (en) Therapy
IL126972A0 (en) Stimulation of host defense mechanisms against viral challenges
EP0998293A4 (fr) Traitements lies a la cytokine destines a des affections
IL114576A0 (en) Polynucleotide herpes virus vaccine
HUP0100365A3 (en) Combination therapy for the treatment of aids
AU4068897A (en) Human induced tumor protein
AUPO395996A0 (en) Stimulation of host defence mechanisms
GB9702990D0 (en) Virus vaccine
EP0979277A4 (fr) Nouveau gene suppresseur des tumeurs de l'homme
AU6579698A (en) Human tumor suppressor
HU9602191D0 (en) Therapy of rheumatism
GB9620856D0 (en) Virus vaccine
GB9701448D0 (en) Methods of treatment
HK1052937A1 (zh) 疾病之細胞激素相關的治療
GB2333527B (en) Therapeutic gene
TW312148U (en) Improved structure of Chinese medicine cooker
ZA9810306B (en) Combination therapy for the treatment of aids